The application of foam technique to the partial purification of a urine activator of plasma profibrinolysin

Celander, D. R.; Langlinais, R.P.; Guest, M. Mason

doi:10.1016/0003-9861(55)90566-x

Cited by 23 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further characterization of the two endogenous plasminogen activators was made by a num ber of different groups. [23][24][25][26][27][28][29][30] Techniques for purification of urokinase in appreciable quantities led to its introduction as a therapeutic alternative to streptokinase. [31][32][33][34][35][36][37][38][39] Though delayed by initial difficulties in isolation and purification, recombinant tissue plasminogen activator is now pro duced in large quantities through the use of recombinant molecular biologic techniques.…”

mentioning

confidence: 99%

The Fibrinolytic System in Neoplasia

Bell¹

1996

Semin Thromb Hemost

View full text Add to dashboard Cite

During activation of the fibrinolytic system plasminogen is converted to plasmin by tissue plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). t-PA is predominantly released from endothelial cells, u-PA primarily by renal parenchymal cells. The activation of plasminogen is regulated by plasminogen activator inhibitor-1 (PAI-1), plasmin is controlled by alpha 2-plasmin inhibitor. The fibrinolytic system is not only involved in the intravascular dissolution of fibrin (thrombi), it also plays a vital role in normal physiologic reproduction, wound repair, angiogenesis, and tissue remodeling. Fibrinolysis is also a vital component in the pathogenesis of neoplastic disease. It is essential in releasing cells from their primary site of origin, providing nutrition for neoplastic cell growth and promoting cell mobility and motility. In neoplastic cells the degradation of the extracellular matrix proteins is facilitated by excessive expression of u-PA, t-PA, and u-PAR. In many forms of carcinoma increased expression of u-PAR and u-PA is associated with significantly shorter survival. Greater expression of u-PA in breast cancer cells, for example, is associated with shorter survival and increased relapse rate. Progressively aggressive neoplastic cells evidence high expression of u-PA and u-PAR activities, variable expression of t-PA, and enhanced PAI-1 and PAI-2 activities. In acute nonlymphocytic leukemias, poor outcome correlates with high t-PA levels. In acute progranulocytic leukemia there is a high incidence of DIC. Neoplastic prostatic tissue also expresses high u-PA activity and the more aggressive the cell line, the greater the number of u-PAR and the higher the u-PA activity. In gynecologic malignancies, a greater expression of u-PA in combination with cathepsin D is associated with widespread disease and poor prognosis. High u-PA values were also seen in patients with brain, gastric, and hepatic malignancies. It is evident that the plasminogen-plasmin system is a vital component in the biology of neoplastic disease and that it is, in theses conditions, in no way beneficial to the host.

show abstract

mentioning

confidence: 99%

The Fibrinolytic System in Neoplasia

Bell¹

1996

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…During the several years following its discovery, methods for limited purification of urokinase were reported (Von Kaulla, 1954;Celander et al, 1955; Ploug and Kjeldgaard, 1957; Celander and Guest, 1960;Sgouris et al, 1960Sgouris et al, , 1962. More recently, in a brief communication, Lesuk et al (1965) described the preparation of crystalline urokinase.…”

mentioning

confidence: 99%

The Isolation and Characterization of Plasminogen Activators (Urokinase) from Human Urine^*

White¹,

Barlow²,

Mozen³

1966

Biochemistry

240

View full text Add to dashboard Cite

show abstract

“…A complete (direct) activator of plasminogen named urokinase was found to be present in urine. The observation that urokinase accumulated in the urine foam in concentrations approximately 100-fold in potency over that in urine enabled Celander and co-workers to prepare urokinase in large quantities (Celander et al, 1955). Urokinase is a colourless, water-soluble protein which, when pure, is fairly stable within a large pH and temperature range .…”

Section: Discussionmentioning

confidence: 99%

Urokinase in the management of vitreous hemorrhage.

Chapman-Smith¹,

Crock²

1977

British Journal of Ophthalmology

View full text Add to dashboard Cite

The application of foam technique to the partial purification of a urine activator of plasma profibrinolysin

Cited by 23 publications

References 3 publications

The Fibrinolytic System in Neoplasia

The Fibrinolytic System in Neoplasia

The Isolation and Characterization of Plasminogen Activators (Urokinase) from Human Urine^*

Urokinase in the management of vitreous hemorrhage.

Contact Info

Product

Resources

About

The application of foam technique to the partial purification of a urine activator of plasma profibrinolysin

Cited by 23 publications

References 3 publications

The Fibrinolytic System in Neoplasia

The Fibrinolytic System in Neoplasia

The Isolation and Characterization of Plasminogen Activators (Urokinase) from Human Urine*

Urokinase in the management of vitreous hemorrhage.

Contact Info

Product

Resources

About

The Isolation and Characterization of Plasminogen Activators (Urokinase) from Human Urine^*